Department of Dermatology and Venereology, Al-Azhar University, Demietta 34517, Egypt
Mini Review
Disclosing the Capability of Biomarkers: Utilizing Precision Medicine to Evaluate Omalizumab Treatment Response in Chronic Urticaria
Author(s): Lara Townley*
Chronic urticaria, characterized by recurrent and persistent hives and itching, poses significant challenges in terms of effective treatment options.
Omalizumab, a monoclonal antibody targeting Immunoglobulin E (IgE), has shown promising results in managing chronic urticaria; however, not all
patients respond equally to this therapy. The advent of precision medicine has opened up new avenues for tailoring treatment approaches based
on individual patient characteristics and biomarker analysis. This review explores the capability of biomarkers in evaluating the treatment response
to omalizumab in chronic urticaria. Several potential biomarkers, including serum levels of IgE, IgE autoantibodies, and various inflammatory
mediators, have been investigated as indicators of treatment response. By analyzing these biomarkers, clinicians can gain valuable insights into
t.. Read More»
DOI:
10.37421/2155-9929.2023.14.580
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 